{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T15:29:37Z","timestamp":1745854177864},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cidjournal.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.clindermatol.2014.12.010","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T18:13:09Z","timestamp":1418062389000},"page":"333-339","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Antifungal therapy for onychomycosis in children"],"prefix":"10.1016","volume":"33","author":[{"given":"Stephanie","family":"Feldstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Totri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila Fallon","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2 Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0005","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.12788\/j.sder.0015","article-title":"Diagnosis, clinical implications, and complications of onychomycosis","volume":"32","author":"Rich","year":"2013","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0010","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(97)80215-0","article-title":"Onychomycosis in children: prevalence and treatment strategies","volume":"36","author":"Gupta","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1525-1470.2008.00832.x","article-title":"A population-based study of toenail onychomycosis in Israeli children","volume":"26","author":"Leibovici","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clindermatol.2009.12.006","article-title":"Onychomycosis","volume":"28","author":"Welsh","year":"2010","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","article-title":"A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns","volume":"43","author":"Ghannoum","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0030","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/archderm.1997.03890450124022","article-title":"Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions","volume":"133","author":"Elewski","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0035","first-page":"762","article-title":"Onychomycosis: current trends in diagnosis and treatment","volume":"88","author":"Westerberg","year":"2013","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5021\/ad.2013.25.3.327","article-title":"Onychomycosis in children: an experience of 59 cases","volume":"25","author":"Kim","year":"2013","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0045","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/pde.12064","article-title":"Onochomycosis does not always require systemic treatment for cure: a trial using topical therapy","volume":"30","author":"Friedlander","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.4103\/0378-6323.120724","article-title":"Prevalence and risk factors of onychomycosis in primary school children living in rural and urban areas in Central Anatolia of Turkey","volume":"79","author":"Gulgun","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4103\/0378-6323.86475","article-title":"Onychomycosis: diagnosis and management","volume":"77","author":"Singal","year":"2011","journal-title":"Ind J Dermatol Venerol Leprol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/pde.12048","article-title":"Systemic antifungals to treat onychomycosis in children: a systematic review","volume":"30","author":"Gupta","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0065","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0190-9622(09)80305-8","article-title":"Mechanisms of action of systemic antifungal agents","volume":"28","author":"Elewski","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0070","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1111\/j.1439-0507.2011.02038.x","article-title":"Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US","volume":"54","author":"Van Duyn","year":"2011","journal-title":"Mycoses"},{"author":"Novartis Pharmaceuticals corporation","key":"10.1016\/j.clindermatol.2014.12.010_bb0075"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1468-3083.2008.03036.x","article-title":"The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis","volume":"23","author":"Gupta","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.0736-8046.2004.21117.x","article-title":"Onychomycosis in children: a brief overview with treatment strategies","volume":"21","author":"Gupta","year":"2004","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2133.2003.05728.x","article-title":"Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis","volume":"150","author":"Gupta","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2001.117520","article-title":"Reversible agranulocytosis associated with oral terbinafine in a pediatric patient","volume":"45","author":"Aguilar","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.clindermatol.2013.06.011","article-title":"Therapies for the treatment of onychomycosis","volume":"31","author":"Gupta","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1365-2133.1997.tb14902.x","article-title":"A double blind randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of tonenail onochomycosis","volume":"136","author":"Havu","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0733-8635(03)00030-5","article-title":"Efficacy and safety of itraconazole use in children","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0190-9622(97)70275-5","article-title":"Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophte molds and in mixed infections with dermatophytes and molds: a multicenter study with 36 patients","volume":"36","author":"De Doncker","year":"1997","journal-title":"J Am Acad Dermatol"},{"author":"Janssen","key":"10.1016\/j.clindermatol.2014.12.010_bb0120"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0125","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1345\/aph.1M165","article-title":"Efficacy of fluconazole for the treatment of onochomycosis","volume":"43","author":"Brown","year":"2009","journal-title":"Ann Pharmacother"},{"author":"Pfizer","key":"10.1016\/j.clindermatol.2014.12.010_bb0130"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0135","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-012-1468-2","article-title":"Safety of fluconazole in paediatrics: a systematic review","volume":"69","author":"Egunsola","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0140","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0733-8635(03)00027-5","article-title":"The use of oral antifungal agents to treat onychomycosis","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"},{"issue":"Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1461-1244.2004.02380.x","article-title":"Ciclopirox: a broad-spectrum antifungal with antibacterial and antiinflammatory properties","volume":"43","author":"Gupta","year":"2004","journal-title":"Int J Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0150","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0926-9959(94)00074-A","article-title":"Mechanism of action of antifungals and combination therapy","volume":"4","author":"Polak-Wyss","year":"1995","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0155","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.clindermatol.2013.06.010","article-title":"Improved efficacy in onychomycosis therapy","volume":"31","author":"Gupta","year":"2013","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0160","first-page":"761","article-title":"Congenital candidal onychomycoses: effective cure with ciclopirox olamine 8% nail lacquer","volume":"26","author":"Sardana","year":"2009","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0165","first-page":"108","article-title":"Onychomycosis in a very young child","volume":"49","author":"Zac","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0170","first-page":"29","article-title":"Trichophyton rubrum onychomycosis in a 10-week-old infant","volume":"36","author":"Sachdeva","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1046\/j.1468-3083.2001.00182.x","article-title":"Superficial white onychomycosis in a 3-year-old human immuno-deficiency virus-infected child","volume":"15","author":"Pena-Penabad","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0180","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1525-1470.2006.00272.x","article-title":"Rapid response of distal subungual onychomycosis to 5% amorolfine nail lacquer in a 20-month-old healthy infant","volume":"23","author":"Hsu","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0185","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0190-9622(97)70321-9","article-title":"Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature","volume":"36","author":"Ploysangam","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl. 4","key":"10.1016\/j.clindermatol.2014.12.010_bb0190","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1067\/mjd.2000.109072","article-title":"Dermatopharmacology of ciclopirox nail lacquer topical solution 8% in the treatment of onychomycosis","volume":"43","author":"Bohn","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0195","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.2165\/11538110-000000000-00000","article-title":"Ciclopirox: recent nonclinical and clinical data relevant to its use as a topical antimycotic agent","volume":"70","author":"Subissi","year":"2010","journal-title":"Drugs"},{"issue":"4 Suppl.","key":"10.1016\/j.clindermatol.2014.12.010_bb0200","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0205","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/j.1468-3083.2009.03164.x","article-title":"An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis","volume":"23","author":"Baran","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0210","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/09546630500420183","article-title":"Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis","volume":"16","author":"Avner","year":"2005","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0215","first-page":"481","article-title":"Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study","volume":"4","author":"Gupta","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0220","doi-asserted-by":"crossref","first-page":"393","DOI":"10.4103\/0378-6323.37056","article-title":"An open randomized comparative study to test the efficacy and safety of oral terbinafine pulse as a monotherapy and in combination with topical ciclopirox olamine 8% or topical amorolfine hydrochloride 5% in the treatment of onychomycosis","volume":"73","author":"Jaisawl","year":"2007","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0225","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000247588","article-title":"Preclinical data and mode of action of amorolfine","volume":"184","author":"Polak","year":"1992","journal-title":"Dermatology"},{"author":"Medicines and Healthcare Products Regulatory Agency","key":"10.1016\/j.clindermatol.2014.12.010_bb0230"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0733-8635(03)00025-1","article-title":"The use of topical therapies to treat onychomycosis","volume":"21","author":"Gupta","year":"2004","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0240","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000353667","volume":"227","author":"Paul","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0245","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2133.2007.07974.x","volume":"157","author":"Baran","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0250","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1046\/j.1365-2133.2000.03545.x","article-title":"A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine alone in the treatment of dermatophyte toenail onychomycoses affecting the matrix region","volume":"142","author":"Baran","year":"2000","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0255","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1046\/j.1365-2133.2003.05381.x","article-title":"A randomized trial of amorolfne 5% nail lacquer in association with itraconaozle pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis","volume":"149","author":"Rigopoulos","year":"2003","journal-title":"Br J Dermatol"},{"issue":"Suppl. 60","key":"10.1016\/j.clindermatol.2014.12.010_bb0260","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2133.2001.145s60021.x","article-title":"Amorolfine and itraconazole combination for severe toenail onychomycosis: results of an open randomized trial in Spain","volume":"145","author":"Lecha","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0265","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s40265-013-0152-x","article-title":"Efinaconazole: first global approval","volume":"73","author":"Patel","year":"2013","journal-title":"Drugs"},{"issue":"2 Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0270","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.12788\/j.sder.0016","article-title":"Current and emerging options in the treatment of onychomycosis","volume":"32","author":"Elewski","year":"2013","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0275","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2012.10.013","article-title":"Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies","volume":"68","author":"Elewski","year":"2013","journal-title":"J Am Acad Dermatol"},{"author":"Tavaborole (AN2690)","key":"10.1016\/j.clindermatol.2014.12.010_bb0280"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0285","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7547\/0960465","article-title":"Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial","volume":"96","author":"Jennings","year":"2006","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0290","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.jfas.2008.12.012","article-title":"Efficacy of debridement alone versus debridement combined with topical antifungal nail lacquer for the treatment of pedal onychomycosis: a randomized, controlled trial","volume":"48","author":"Malay","year":"2009","journal-title":"J Foot Ankle Surg"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0295","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/0378-6323.95444","article-title":"Nail avulsion: indications and methods (surgical nail avulsuion)","volume":"78","author":"Pandhi","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0300","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jpedsurg.2007.12.042","article-title":"Treatment of ingrown toenails in the pediatric population","volume":"43","author":"Yang","year":"2008","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0305","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1046\/j.1525-1470.2000.01761.x","article-title":"Onochomycosis in children: treatment with bifonazole-urea","volume":"17","author":"Bonifaz","year":"2000","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0310","doi-asserted-by":"crossref","first-page":"20392","DOI":"10.5070\/D31911020392","article-title":"Urea: a comprehensive review of the clinical literature","volume":"19","author":"Pan","year":"2013","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0315","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3109\/09546634.2011.588191","article-title":"A comparative evaluation of combination therapy of fluconazole 1% and urea 40% compared with fluconazole 1% alone in a nail lacquer for treatment of onychomycosis: therapeutic trial","volume":"23","author":"Bassiri-Jahromi","year":"2012","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0320","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2310\/7750.2012.12060","article-title":"Laser therapy for onychomycosis","volume":"17","author":"Gupta","year":"2013","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0325","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1529-8019.2012.01519.x","article-title":"Medical devices for the treatment of onychomycosis","volume":"25","author":"Gupta","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0330","first-page":"4","article-title":"Device based therapy for onychomycosis treatment","volume":"17","author":"Gupta","year":"2012","journal-title":"Skin Therapy Lett"},{"issue":"Suppl. 65","key":"10.1016\/j.clindermatol.2014.12.010_bb0335","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.149.s65.5.x","article-title":"Onychomycosis in clinical practice: Factors contributing to recurrence","volume":"149","author":"Scher","year":"2003","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"10.1016\/j.clindermatol.2014.12.010_bb0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1468-3083.2005.01282.x","article-title":"Patients at risk of onychomycosis\u2014risk factor identification and active prevention","volume":"19","author":"Tosti","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2014.12.010_bb0345","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0733-8635(03)00026-3","article-title":"How to improve cure rates for the management of onychomycosis","volume":"21","author":"Gupta","year":"2003","journal-title":"Dermatol Clin"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14003095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X14003095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T14:30:47Z","timestamp":1690727447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X14003095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0738081X14003095"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.12.010","relation":{},"ISSN":["0738-081X"],"issn-type":[{"type":"print","value":"0738-081X"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antifungal therapy for onychomycosis in children","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2014.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}